 Shoreline Biosciences Inc and BeiGene Ltd NASDAQ: BGNE have announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of NK-based cell therapeutics with Shorelines iPSC NK cell technology for different malignancies. Under the terms of the agreement, Shoreline will receive an upfront cash payment of 45 million and will be eligible to receive additional RD funding, milestone payments. 